Effect of one‐week oral or inhaled salbutamol treatment with washout on repeated sprint performance in trained subjects
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of one‐week oral or inhaled salbutamol treatment with washout on repeated sprint performance in trained subjects. / Eibye, Kasper; Jacobson, Glenn A; Bengtsen, Kasper; Jessen, Søren; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten.
In: Translational Sports Medicine, Vol. 4, No. 2, 2021, p. 241-249.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of one‐week oral or inhaled salbutamol treatment with washout on repeated sprint performance in trained subjects
AU - Eibye, Kasper
AU - Jacobson, Glenn A
AU - Bengtsen, Kasper
AU - Jessen, Søren
AU - Backer, Vibeke
AU - Bangsbo, Jens
AU - Hostrup, Morten
N1 - CURIS 2021 NEXS 221
PY - 2021
Y1 - 2021
N2 - Background: Acute and chronic supratherapeutic treatment with the commonly used beta2-agonist salbutamol has the potential to enhance sprint performance and muscle strength. However, little is known about the performance effects of short-term daily permitted inhaled treatment vs oral prohibited treatment in accordance with the 2020 Prohibited List issued by the World Anti-Doping Agency (WADA).Methods: Herein, we investigated the effect of twice-daily treatment with 400 μg inhaled or 4 mg oral salbutamol for 1 week on repeated sprint performance in 19 healthy well-trained men and women utilizing a randomized open-label crossover design. Before and after each treatment period, and a 12-16 hours washout to avoid an acute effect of salbutamol, subjects performed a repeated sprint test (3 × 30-second Wingate).Results: Neither oral nor inhaled salbutamol enhanced peak power (oral; 3.0 W; 95% CI −6.8 to 12.8 W; and inhaled; −3.8 W; 95% CI −14.3 to 6.8 W) or mean power (oral; −2.1 W; 95% CI −4.7 to 8.9 W and inhaled; −1.6 W; 95% CI −5.6 to 8.9 W) during the repeated sprint test irrespective of gender.Conclusions: These findings indicate that 1 week is insufficient for salbutamol to induce any relevant effect on repeated sprint performance in trained individuals.
AB - Background: Acute and chronic supratherapeutic treatment with the commonly used beta2-agonist salbutamol has the potential to enhance sprint performance and muscle strength. However, little is known about the performance effects of short-term daily permitted inhaled treatment vs oral prohibited treatment in accordance with the 2020 Prohibited List issued by the World Anti-Doping Agency (WADA).Methods: Herein, we investigated the effect of twice-daily treatment with 400 μg inhaled or 4 mg oral salbutamol for 1 week on repeated sprint performance in 19 healthy well-trained men and women utilizing a randomized open-label crossover design. Before and after each treatment period, and a 12-16 hours washout to avoid an acute effect of salbutamol, subjects performed a repeated sprint test (3 × 30-second Wingate).Results: Neither oral nor inhaled salbutamol enhanced peak power (oral; 3.0 W; 95% CI −6.8 to 12.8 W; and inhaled; −3.8 W; 95% CI −14.3 to 6.8 W) or mean power (oral; −2.1 W; 95% CI −4.7 to 8.9 W and inhaled; −1.6 W; 95% CI −5.6 to 8.9 W) during the repeated sprint test irrespective of gender.Conclusions: These findings indicate that 1 week is insufficient for salbutamol to induce any relevant effect on repeated sprint performance in trained individuals.
KW - Faculty of Science
KW - Asthma
KW - Beta2-agonist
KW - Doping
KW - Exercise-induced bronchoconstriction
KW - Performance
KW - Salbutamol
KW - Wingate
U2 - 10.1002/tsm2.210
DO - 10.1002/tsm2.210
M3 - Journal article
VL - 4
SP - 241
EP - 249
JO - Translational Sports Medicine
JF - Translational Sports Medicine
SN - 2573-8488
IS - 2
ER -
ID: 272652654